AFR Exclusive, page-54

First 54 Last

Share
Profile

Follow
phillit

389 Posts.

63

13/03/22

17:16

Post #: 60164941
Share

Originally posted by Taurean7: ↑

Phil

There is very little difference in ownership laws relating to real property or intellectual property. Recognising this close relationship helps with understanding Anagenics’ current position.

If someone either buys a property or spends money establishing one they are the legal owner. Any builder/inventor employed in developing the property (eg Halasz) has no ownership rights to determine how the property is used.

Legal proof of a property’s ownership is demonstrated through a patent or a certificate of title registered in the owner’s name.

Owners are required to meet the ongoing expenses associated with maintaining the property. They benefit from any increase in its value, which can be transferred though sale.

Owners have the sole right of determining whether to benefit from the use of the property themselves or to rent (licence) its use to others for an agreed income. If someone does not wish to accept the rental/licensing agreement because they don’t want to interact with the landlord then their only option is to look elsewhere.

If ownership of the property changes the terms of the rental/licensing agreement remain unchanged. This holds also if the owner were to die, in which case the property then is transferred intact to their beneficiaries or creditors.

Similar to a property investor Anagenics owns a property portfolio, the exclusive licensee of the complete portfolio is Lyramid, and any owners of Lyramid are legally committed to meeting the terms of the licensing agreement.

Splitting the portfolio would require the drafting of a new agreement.

I feel I should add that I spent fifteen years with an involvement in the drafting of patents and licensing agreements for the protection and commercialisation of scientific intellectual property.

Hope this helps.

Cheers

T7

Expand

Originally posted by Taurean7: ↑

Phil

I don’t understand why you continue to raise the same point about IP ownership. Nobody is disagreeing with you. I made the same point in my initial post.

“My expectation is that a buyer at that time would wish to clean things up and purchase the IP as well rather than retain a commitment to pay fees and royalties for years.”

Understandably, as you have pointed out, no-one is interested in buying it until its value has been proven (proof of concept). That’s what Roquefort now is intending to do after Cellmid failed to raise the necessary capital to do it.

Roquefort has paid for the exclusive right to establish that value. If successful then both the licensed rights that Roquefort has paid for and Anagenics’ patent portfolio that the rights are based upon will become quiet valuable (and saleable presumably).

I suggest you read my initial post again if the matter still is unclear.

Cheers

Expand

If you are not disagreeing with me, I do not understand why you are posting "help" and "clarification" regarding my posts. Obviously no help and clarification is needed from you.

I hope that helps and clears the air for you.

AN1 Price at posting: 4.8¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

TON

Triton snaffles 588 square km gold-copper play in Mozambique

DRE

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 33 more messages in this thread...

First 54 Last

Add AN1 (ASX) to my watchlist

(20min delay)
Last 0.8¢		Change 0.000(0.00%)		Mkt cap ! $3.690M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

AFR Exclusive, page-54

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Triton snaffles 588 square km gold-copper play in Mozambique

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Featured News

AFR Exclusive, page-54

Top Stories

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Triton snaffles 588 square km gold-copper play in Mozambique

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Featured News